-
Pogacar expects Vingegaard Tour de France battle to last 'years'
-
Japan deploys bear cameras in mountains as attacks surge
-
New York ready for epic Swift-Kelce love story wedding
-
Djokovic has history in his sights at Wimbledon
-
Wildfires rage in southern France, 3,000 people evacuated
-
Ovechkin returning to Caps for 22nd NHL season
-
Hamilton gives F1 a piece of his mind over Lego cars
-
Faster than Mbappe: Australia flyer Bos races into World Cup conversation
-
Hong Kong bookseller once held in China dies in Taiwan
-
Trump wants 'senseless killing' in Ukraine to end: US official
-
Venezuelan rescue brings hope to nation in mourning
-
Eala writes history for Philippines in 'electric' Wimbledon atmosphere
-
Macabre night in La Guaira, Venezuela's earthquake epicenter
-
Wolff urges 'perspective' as Russell chases Mercedes' teammate Antonelli
-
Tesla global auto sales jump 25% in 2nd quarter, beating expectations
-
Superb Swiatek, Zverev cruise into Wimbledon last 32
-
Zverev routs Royer to reach Wimbledon third round
-
Ukraine, Russia vow escalation after Moscow attack kills 21 in Kyiv
-
Hot spell roasts eastern US ahead of holiday weekend
-
Slowing US job growth poses midterms challenge for Trump
-
Hamilton cools fans Ferrari fervour
-
Klopp poised to replace Nagelsmann as Germany coach: reports
-
Venezuela's diaspora searches for quake victims on social media
-
More than 400 dead in DR Congo's spreading Ebola outbreak
-
Albanian clashes as protest over Trump-linked resort boils over
-
Hot spell roasts eastern US as holiday weekend approaches
-
Desire key to Pogacar dominance, says former Tour king Froome
-
Superb Swiatek storms into Wimbledon last 32, Zverev waits
-
Rescuers dig out Venezuelan man eight days after quakes
-
Russian strikes kill 21 in biggest ever attack on Kyiv, mayor says
-
Anderson closes in on record Man City move
-
Swiatek sees off Pliskova to race into Wimbledon third round
-
England change five for South Africa Test
-
Dollar down, stocks shine after disappointing US jobs data
-
Lock Alemanno to make 100th Pumas appearance against Scotland
-
US job growth slows, posing questions for Trump before midterms
-
US posts weaker-than-expected job growth in June
-
Chanel eyes menswear with Charvet shirtmaker takeover
-
UK PM says 'deeply sorry' for decades of forced adoptions
-
Chanel eyes menswear with Charvet shirtmaker takevoer
-
Almost 1.2 mn apply for Spain's migrant regularisation
-
'I grabbed my child': Kyiv residents face devastation of biggest Russian barrage of war
-
Ukrainian state ordered Nord Stream sabotage: German prosecutors
-
Former top jockey Dettori breaks ribs in car crash
-
Swiatek, Zverev aiming to lay down Wimbledon markers
-
Rees-Zammit returns to wing as Wales face Fiji
-
German ruling coalition agrees on major reform package
-
Renovations on historic Paris Opera house extended by three years
-
European stocks climb after Asia rout
-
Thailand denies viral claim Macron knelt before king
Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
W.Lapointe--BTB